Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the my...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medical Journals Sweden
2024-03-01
|
| Serie: | Acta Oncologica |
| Soggetti: | |
| Accesso online: | https://medicaljournalssweden.se/actaoncologica/article/view/34139 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|